peptide backbone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-22. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
=== Non-neural sources === Endogenous oxytocin concentrations in the brain are as much as 1000-fold higher than peripheral levels. Outside the brain, oxytocin-containing cells have been identified in several diverse tissues, including in females in the corpus luteum and the placenta; in males in the testicles' interstitial cells of Leydig; and in both sexes in the retina, the adrenal medulla, the thymus and the pancreas. The finding of significant amounts of this classically "neurohypophysial" hormone outside the central nervous system raises many questions regarding its possible importance in these diverse tissues. The Leydig cells in some species have been shown to possess the biosynthetic machinery to manufacture testicular oxytocin de novo, to be specific, in rats (which can synthesize vitamin C endogenously), and in guinea pigs, which, like humans, require an exogenous source of vitamin C in their diets. Oxytocin is synthesized by corpora lutea of several species, including ruminants and primates. Along with estrogen, it is involved in inducing the endometrial synthesis of prostaglandin F2α to cause regression of the corpus luteum.
== Selective ligands == Several selective ligands for the melanocortin receptors are known, and some synthetic compounds have been investigated as potential tanning, anti-obesity and aphrodisiac drugs, with tanning effects mainly from stimulation of MC1, while anorectic and aphrodisiac effects appear to involve both MC3 and MC4. MC1, MC3 and MC4 are widely expressed in the brain, and are also thought to be responsible for effects on mood and cognition.
=== Climate and Health === Beginning in 2024, the HISP Centre received a grant from the Wellcome Trust to develop and pilot new DHIS2 functionalities for climate and health use cases. This has led to the development of tools for integrating weather, climate, and environmental data into DHIS2 and harmonizing it with health data and for predictive modeling of climate-sensitive diseases.
==== Temporary spacer ==== A synthetic material may be used as a temporary antibiotic spacer before being replaced by a more permanent material. For example, the Masquelet procedure consists of initially using PMMA mixed with an antibiotic (vancomycin or gentamicin) for 4–12 weeks, and then replacing the space with an autologous bone graft. It can be used to treat posttraumatic bone defects.
Newsom has been widely considered a prominent figure in liberal American politics during the 2020s. In 2023, he launched Campaign for Democracy, a political action committee to take on "authoritarian leaders" in the U.S. It is thought to be a starting point for a possible 2028 presidential bid. By July 2024, Campaign for Democracy had raised $24 million for direct contributions to candidates and other spending. The group is not subject to contribution limits and can coordinate with Newsom as long as he is not a candidate for federal office. Many journalists and political analysts have mentioned Newsom as a presidential hopeful. According to a June 2023 poll by NewsNation, 22% of California voters wanted him to enter the 2024 U.S. presidential election. In May 2023, Arnold Schwarzenegger said it was a "no-brainer" that Newsom would someday run for president. An April 2023 The Hill article by Sharon Udasin also discussed the inevitability of a Newsom presidential run. In September 2022, Newsom said he would not run for president in 2024, citing his "vulnerable" 2021 recall. After his 2022 reelection, he told White House staff that he would not challenge President Joe Biden in the 2024 Democratic Party presidential primaries; he endorsed Biden's reelection campaign on April 25, 2023. Newsom has become an outspoken critic of the policies of Florida governor Ron DeSantis, denouncing DeSantis's orchestration of the Martha's Vineyard migrant airlift. DeSantis responded by saying California has "huge problems" and dared Newsom to run against Biden.
Sources: en.wikipedia.org
== Function == Cavin-2 is required for blood vessel formation (angiogenesis) in humans and zebrafish and required also for the endothelial cell proliferation, migration and invasion in humans. Cavin-2 plays an important role in endothelial cell maintenance by regulating eNOS activity. Cavin-2 controls the generation of nitric oxide (NO) in human endothelial cells by controlling the activity and stability of the protein endothelial nitric-oxide synthase (eNOS).
== Pharmacology == Eugenol and thymol possess general anesthetic properties. Like many other anesthetic agents, these 2-alkyl(oxy)phenols act as positive allosteric modulators of the GABAA receptor. Although eugenol and thymol are too toxic and not potent enough to be used clinically, these findings led to the development of 2-substituted phenol anesthetic drugs, including propanidid (later withdrawn) and the widely used propofol. Eugenol and the structurally similar myristicin have the common property of inhibiting MAO-A and MAO-B in vitro. In humans, complete excretion occurs within 24 hours and metabolites are mostly conjugates of eugenol.
Director, Chuckling Goat. For services to Charity and to Innovation in Wales. Evelyn Mary Joy. Agent, Buckingham Conservative Association. For Political and Public Service. James Michael Keggen. Coxswain, Port St Mary Lifeboat Station, Royal National Lifeboat Institution. For voluntary services to Maritime Safety. Sharon Elaine Kelly. Project Manager, Royston Youth Action. For services to Young People. Lindsey Kemp. Officer, National Crime Agency. For services to Law Enforcement. Maurice Joseph Kennedy. Volunteer, Transport Training Board. For services to the Transport and Logistics Industries of Northern Ireland and Great Britain. Christine Anne Kenyon. Deputy Principal, The Manchester College, Greater Manchester. For services to Further Education. Michael Kettle. Explosives Officer, Metropolitan Police Service. For services to Bomb Disposal. Helen Morag Keys. Entrepreneur, Queen's University's Students' Union. For services to Entrepreneurship and Innovation in Farming. Jasdeep Hari Bhajan Singh Khalsa. Founder, The Sikher Project. For charitable services to the Sikh Community. Professor Saye Hock Khoo. Professor of Pharmacology and Therapeutics, University of Liverpool. For services to Infectious Diseases and Pharmacology. Virginia Kiddle. Officer, National Crime Agency. For services to Law Enforcement. Amy Kilby. UK Representative, International Project Management Organisation. For services to Military Communications. James Kilpatrick. Chair, RVH Liver Support Group. For services to People with Liver Disease and their Carers in Northern Ireland. Charline Zephoria King.
Newborn screening (NBS) is a public health program of screening in infants shortly after birth for conditions that are treatable, but not clinically evident in the newborn period. The goal is to identify infants at risk for these conditions early enough to confirm the diagnosis and provide intervention that will alter the clinical course of the disease and prevent or ameliorate the clinical manifestations. NBS started with the discovery that the amino acid disorder phenylketonuria (PKU) could be treated by dietary adjustment, and that early intervention was required for the best outcome. Infants with PKU appear normal at birth, but are unable to metabolize the essential amino acid phenylalanine, resulting in irreversible intellectual disability. In the 1960s, Robert Guthrie developed a simple method using a bacterial inhibition assay that could detect high levels of phenylalanine in blood shortly after a baby was born. Guthrie also pioneered the collection of blood on filter paper which could be easily transported, recognizing the need for a simple system if the screening was going to be done on a large scale. Newborn screening around the world is still done using similar filter paper. NBS was first introduced as a public health program in the United States in the early 1960s, and has expanded to countries around the world. Screening programs are often run by state or national governing bodies with the goal of screening all infants born in the jurisdiction for a defined panel of treatable disorders.
== Awards == Gavi was awarded the 2019 Lasker-Bloomberg Public Service Award for "providing sustained access to childhood vaccines around the globe, thus saving millions of lives, and for highlighting the power of immunization to prevent disease". Gavi was nominated for the 2021 Nobel Peace Prize by Norwegian MP Carl-Erik Grimstad. Gavi was awarded the Sunhak Peace Prize in 2022 for promoting vaccine equity at the forefront of COVID-19 by leading COVAX, and for improving global health by increasing access to vaccines for children in vulnerable countries.
Sources: en.wikipedia.org
Jerky is made from domesticated animals as well as game animals. Jerky from domesticated animals includes llama, beef, pork, goat and mutton or lamb and game animals such as guanaco, deer, kudu, springbok, kangaroo, and bison are also used. Other animals such as turkey, ostrich, calamari, salmon, chicken, duck, goose, shrimps, oxen, squids, octopuses, alligator, pigeon, crocodile, tuna, emu, horse, camel, lion, bear, snake and earthworm have entered the global, national, regional or local market with varying degrees of success. Most fat must be trimmed from the meat prior to drying, as fat increases the chances of spoilage (modern vacuum packing and chemical preservatives have served to help prevent these risks). The meat must be dried quickly to limit bacterial growth during the critical period when the meat is not yet dry. To dry quickly without high temperature, which would cook the meat, the meat must be sliced or pressed thin. Salt is the most commonly added ingredient and is used to improve flavor, enhance the storage life and remove moisture from the product. Spices such as black pepper or garlic are other common ingredients. Ingredients such as soy sauce, Worcestershire sauce, sugar, teriyaki or barbecue spice can be added to change the flavor and are usually employed in homemade beef jerky recipes. In industrial settings, large low-temperature drying ovens with many heater elements and fans use exhaust ports to remove moisture-laden air. The combination of fast-moving air and low heat dries the meat to the desired moisture content within a few hours.
In summary, while the first two studies explore the benefits and challenges of exercise in different diabetes types, the third study stresses the importance of accurate diagnosis and management before engaging in physical activity. Together, these studies highlight the complex interactions between exercise, diabetes type, treatment, and individual challenges.
Numerous studies suggest that disruption of melatonin production may underlie the association between light exposure before and during sleep and impaired sleep quality. It has also been suggested that light-induced disruption of melatonin production may potentially affect cognitive, emotional, cardiovascular, and metabolic functions.
=== Pharmacokinetics === When used as an injectable it typically begins working within four minutes and lasts for half an hour to three hours. Lidocaine is about 95% metabolized (dealkylated) in the liver mainly by CYP3A4 to the pharmacologically active metabolites monoethylglycinexylidide (MEGX) and then subsequently to the inactive glycine xylidide. MEGX has a longer half-life than lidocaine, but also is a less potent sodium channel blocker. The volume of distribution is 1.1 L/kg to 2.1 L/kg, but congestive heart failure can decrease it. About 60% to 80% circulates bound to the protein alpha1 acid glycoprotein. The oral bioavailability is 35% and the topical bioavailability is 3%. Lidocaine efficacy may be reduced in tissues that are inflamed, due to competing inflammatory mediators. The elimination half-life of lidocaine is biphasic and around 90 min to 120 min in most people. This may be prolonged in people with hepatic impairment (average 343 min) or congestive heart failure (average 136 min). Lidocaine is excreted in the urine (90% as metabolites and 10% as unchanged drug).
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.